HBK INVESTMENTS L P
Institutional investor · Portfolio as of Q4 2019
Top Holdings653 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
| 9.2M | $3B | 28.6% | — | — | — | Increased — | |
WELLCARE HEALTH PLANS INC | 2.4M | $807.5M | 7.8% | — | — | 3 qtrssince 2019-Q2 | Unchanged 0 |
| 1.2M | $506.5M | 4.9% | — | — | — | Decreased — | |
CYPRESS SEMICONDUCTOR CORP | 18M | $419.9M | 4.1% | — | — | 4 qtrssince 2019-Q1 | Unchanged 0 |
| 30.8M | $418.9M | 4.0% | — | — | 2 qtrssince 2019-Q3 | Increased 92 | |
MEDICINES CO | 3.9M | $329.6M | 3.2% | — | — | 1 qtr | New 86 |
| 1M | $327.9M | 3.2% | — | — | — | Increased — | |
| 5.1M | $130.2M | 1.3% | — | — | — | New — | |
STATE STREET SPDR S&P 500 ETF TRUST CL USD INC | 355,000 | $114.3M | 1.1% | $294.23 | 0.00% | 1 qtr | New 69 |
| 500,000 | $106.3M | 1.0% | — | — | — | Unchanged — | |
AMTD IDEA Group | 2M | $99.4M | 1.0% | $50.94 | 0.00% | 1 qtr | New 58 |
| 3.2M | $96M | 0.9% | — | — | — | Decreased — | |
| 56.3M | $85.1M | 0.8% | — | — | 3 qtrssince 2019-Q2 | Decreased 0 | |
TIFFANY & CO NEW | 603,432 | $80.6M | 0.8% | — | — | 1 qtr | New 58 |
SINA CORP | 1.8M | $70.8M | 0.7% | — | — | 4 qtrssince 2019-Q1 | Increased 46 |
| 60M | $62.8M | 0.6% | — | — | 4 qtrssince 2019-Q1 | Increased 49 | |
| 1.5M | $54.1M | 0.5% | — | — | — | Increased — | |
| 42.4M | $54.1M | 0.5% | — | — | 4 qtrssince 2019-Q1 | Decreased 0 | |
| 2.4M | $51.4M | 0.5% | — | — | — | Increased — | |
| 39.7M | $44.1M | 0.4% | — | — | 1 qtr | New 48 |
HBK INVESTMENTS L P manages $10.4B across 653 positions as of Q4 2019. Top holdings: STATE STREET SPDR S&P 500 ETF (28.6%), WCG (7.8%), TESLA INC COM (4.9%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 2.5/5.0.
Active quarter - 100 new positions, 108 exits, 61 increased. Top move: CZRN (INCREASED, conviction 92). Portfolio: $10.4B across 653 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer